Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 7/20 | 0.47 |
| ▸ | CHUK | O15111 | 7/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986296 | 0.91 | MAP3K5 (0.61) | MAP3K5IKBKBCHUKCITMAPT | |
| SCHEMBL2981752 | 0.87 | MAP3K5 (0.55) | MAP3K5IKBKBCHUKCITMAPT | |
| Trifluoroacetic Acid SCHEMBL2988572 | 0.86 | MAP3K5 (0.51) | MAP3K5IKBKBCHUKCITMAPT | |
| SCHEMBL2985551 | 0.84 | MAP3K5 (0.53) | MAP3K5IKBKBCHUKCITMAPT | |
| SCHEMBL2997188 | 0.82 | IKBKB (0.68) | MAP3K5IKBKBCHUKCITCSNK1D | |
| Trifluoroacetic Acid SCHEMBL2985548 | 0.81 | IKBKB (0.62) | MAP3K5IKBKBCHUKCITP2RY14 | |
| SCHEMBL2984098 | 0.81 | MAP3K5 (0.54) | MAP3K5IKBKBCHUKCITMAPT | |
| SCHEMBL2993164 | 0.81 | MAP3K5 (0.54) | MAP3K5IKBKBCHUKCITMAPT | |
| Trifluoroacetic Acid SCHEMBL2994701 | 0.80 | MAP3K5 (0.66) | MAP3K5IKBKBCHUKCITP2RY14 | |
| SCHEMBL2990272 | 0.79 | IKBKB (0.52) | MAP3K5IKBKBCHUKCITCSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | BAMBOROUGH PAUL | 2010-07-15 | — | — | US | disclosed |
| EP-2162455-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | Glaxo Group Limited (GB) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179139-A1 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | NFKBIA, PACSIN2, MAP3K2 | MAP3K5 7/4885IKBKB 11/4885CHUK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.